Celldex Therapeutics (CLDX) Stock Overview
A biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CLDX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Celldex Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$30.09 |
| 52 Week High | US$31.31 |
| 52 Week Low | US$14.40 |
| Beta | 1.26 |
| 1 Month Change | 22.32% |
| 3 Month Change | 12.82% |
| 1 Year Change | 55.50% |
| 3 Year Change | -33.15% |
| 5 Year Change | 14.85% |
| Change since IPO | -73.71% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation
May 06
Celldex Therapeutics: Strong Pipeline But Uncertainties Remain
Apr 22Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation
Jan 28Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns
Jun 07We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth
Jun 05We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth
Jul 07An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued
Apr 21Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth
Feb 27We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate
Sep 07Shareholder Returns
| CLDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 23.7% | 1.2% | -0.6% |
| 1Y | 55.5% | 28.8% | 15.5% |
Return vs Industry: CLDX exceeded the US Biotechs industry which returned 28.8% over the past year.
Return vs Market: CLDX exceeded the US Market which returned 15.5% over the past year.
Price Volatility
| CLDX volatility | |
|---|---|
| CLDX Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CLDX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CLDX's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 198 | Anthony Marucci | www.celldex.com |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation.
Celldex Therapeutics, Inc. Fundamentals Summary
| CLDX fundamental statistics | |
|---|---|
| Market cap | US$2.00b |
| Earnings (TTM) | -US$258.76m |
| Revenue (TTM) | US$1.55m |
Is CLDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLDX income statement (TTM) | |
|---|---|
| Revenue | US$1.55m |
| Cost of Revenue | US$245.07m |
| Gross Profit | -US$243.53m |
| Other Expenses | US$15.23m |
| Earnings | -US$258.76m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.89 |
| Gross Margin | -15,762.39% |
| Net Profit Margin | -16,748.03% |
| Debt/Equity Ratio | 0% |
How did CLDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/02 16:04 |
| End of Day Share Price | 2026/02/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celldex Therapeutics, Inc. is covered by 22 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Edward Nash | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |